11月24日的资金流向数据方面，主力资金净流入144.99万元，占总成交额3.44%，游资资金净流出 468.65万元，占总成交额11.1%，散户资金净流入323.66万元，占总成交额7.67%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-24 | 24.42 | 0.99% | 144.99万 | 3.44% | -468.65万 | -11.10% | 323.66万 | 7.67% liv | | 2025-11-21 | 24.18 | -5.18% | -848.37万 | -13.81% | -188.70万 | -3.07% | 1037.07万 | 16.88% | | 2025-11-20 | 25.50 | -1.01% | -217.43万 | -8.01% | 137.42万 | 5.06% | 80.01万 | 2.95% | | 2025-11- ...

证券之星消息，11月21日南向资金减持11.25万股春立医疗（01858.HK）。近5个交易日中，获南向资金 减持的有3天，累计净减持38.73万股。近20个交易日中，获南向资金增持的有12天，累计净增持157.45 万股。截至目前，南向资金持有春立医疗（01858.HK）4459.61万股，占公司已发行普通股的46.86%。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人 体关节。脊柱类植入产品为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非 洲、大洋洲及欧洲等多个国家和地区。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-21 | 4459.61万 | -11.25万 | -0.25% | | 2025-11-20 | 4470.86 ...

Core Viewpoint - Spring Medical experienced a decline of 5.18% on November 21, with a trading volume of 61.44 million yuan and a market capitalization of 9.275 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its public listing on December 30, 2021 [7][8] Product and Market Position - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, along with a full range of spinal internal fixation systems [2][8] - The company has obtained registration certificates for surgical robots for hip and knee joint surgeries, as well as medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [9] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Spring Medical was 6,164, an increase of 4.12% from the previous period, while the average circulating shares per person decreased by 3.95% [8] - The stock has seen a net outflow of 4.90 million yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5]

证券之星消息，截至2025年11月21日收盘，春立医疗(688236)报收于24.18元，下跌5.18%，换手率 0.86%，成交量2.49万手，成交额6144.13万元。 | 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 92.75亿元 | 109.06亿元 | 38 124 | | 净资产 | 29.86亿元 | 38.93亿元 | 51 124 | | 净利润 | 1.92亿元 | 2.12亿元 | 33 124 | | 市盈率(动) | 36.32 | 54.54 | 42 124 | | 市净率 | 3.11 | 3.77 | 76 124 | | 毛利率 | 67.27% | 51.22% | 27 124 | | 净利率 | 25.34% | 9.57% | 22 124 | | ROE | 6.6% | 0.15% | 33 124 | 11月21日的资金流向数据方面，主力资金净流出848.37万元，占总成交额13.81%，游资资金净流出 188.7万元，占总成交额3.07%，散户资金净流入1037.07万元，占 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Spring Medical, including stock price movement and financing activities [1] - On November 20, Spring Medical's stock fell by 1.01%, with a trading volume of 27.14 million yuan, and a net financing outflow of 393,400 yuan [1] - As of November 20, the total margin balance for Spring Medical was 51.40 million yuan, accounting for 0.70% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with a primary focus on joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, which is a 213.21% increase compared to the previous year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the last three years [3] Group 3 - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 2.96 million shares, while two new shareholders, China Europe Economic Growth Mixed A and Ping An Low Carbon Economy Mixed A, are also noted [3]

数据显示，中欧基金旗下1只基金位居春立医疗十大流通股东。中欧景气精选混合A（020876）三季度 新进十大流通股东，持有股数283.26万股，占流通股的比例为0.74%。根据测算，今日浮亏损失约 368.24万元。连续6天下跌期间浮亏损失708.15万元。 来源：新浪基金∞工作室 中欧景气精选混合A（020876）成立日期2024年4月23日，最新规模10.52亿。今年以来收益40.41%，同 类排名1394/8136；近一年收益46.46%，同类排名748/8056；成立以来收益56.73%。 11月21日，春立医疗跌5.1%，截至发稿，报24.20元/股，成交4929.49万元，换手率0.69%，总市值92.82 亿元。春立医疗股价已经连续6天下跌，区间累计跌幅8.93%。 中欧景气精选混合A（020876）基金经理为张学明。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司 ...

Group 1 - Spring Medical announced a dividend of HKD 0.2304 per share, with an ex-dividend date of November 24, 2025, and a payment date of January 19, 2026. It is classified under the medical devices and supplies sector and is not part of the CSI Central Enterprises Dividend Index or the Hang Seng High Dividend Yield Index [1] - NetEase-S declared a dividend of USD 0.114 per share, with an ex-dividend date of December 4, 2025, and a payment date of December 16, 2025. It falls under the gaming software sector and is excluded from both the CSI Central Enterprises Dividend Index and the Hang Seng High Dividend Yield Index [1] - Kingsoft Technology Industrial announced a dividend of HKD 0.018 per share, with an ex-dividend date of December 24, 2025, and a payment date of January 8, 2026. It is categorized under consumer electronics and is not included in the CSI Central Enterprises Dividend Index or the Hang Seng High Dividend Yield Index [1] - Sa Sa International declared a dividend of HKD 0.0115 per share, with an ex-dividend date of December 3, 2025, and a payment date of December 19, 2025. It is classified in the skincare and cosmetics sector and is not part of the CSI Central Enterprises Dividend Index or the Hang Seng High Dividend Yield Index [1] Group 2 - The CSI Central Enterprises Dividend Index (931233.CSI) selects 50 listed companies with stable dividend levels and high dividend yields from the Hong Kong Stock Connect. As of November 20, the index has a one-year dividend yield of 5.63%, surpassing the 10-year government bond yield of 3.81%. The largest investment vehicle tracking this index is the Hong Kong Central Enterprises Dividend ETF (513910) [3] - The Hang Seng Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI) includes high dividend stocks listed in Hong Kong from mainland companies. As of November 20, this index has a one-year dividend yield of 5.30%, which is higher than the 10-year government bond yield of 3.48%. The only ETF tracking this index is the Hang Seng Dividend ETF (159726) [3]

Group 1 - Spring Medical announced a dividend of HKD 0.2304 per share, with an ex-dividend date of November 24, 2025, and a payment date of January 19, 2026. It is classified under the medical devices and supplies sector and is not part of the Central Enterprises Dividend Index or the High Dividend Yield Index for Mainland Chinese Enterprises [1] - NetEase-S declared a dividend of USD 0.114 per share, with an ex-dividend date of December 4, 2025, and a payment date of December 16, 2025. It falls under the gaming software sector and is also excluded from the aforementioned indices [1] - Kingsoft Technology Industrial announced a dividend of HKD 0.018 per share, with an ex-dividend date of December 24, 2025, and a payment date of January 8, 2026. It is categorized under consumer electronics and is not included in the Central Enterprises Dividend Index or the High Dividend Yield Index [1] - Sa Sa International declared a dividend of HKD 0.0115 per share, with an ex-dividend date of December 3, 2025, and a payment date of December 19, 2025. It is classified in the skincare and cosmetics sector and is excluded from both indices [1] Group 2 - The Central Enterprises Dividend Index (931233.CSI) selects 50 listed companies with stable dividend levels and high dividend yields from the Hong Kong Stock Connect. As of November 20, the index has a one-year dividend yield of 5.63%, surpassing the 10-year government bond yield of 3.81%. The largest investment vehicle tracking this index is the Hong Kong Central Enterprises Dividend ETF (513910) [3] - The Hang Seng Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI) includes high dividend stocks listed in Hong Kong from Mainland companies. As of November 20, this index has a one-year dividend yield of 5.30%, which is higher than the 10-year government bond yield of 3.48%. The only ETF tracking this index is the Hang Seng Dividend ETF (159726) [3]

11月19日，春立医疗跌0.73%，成交额3414.26万元。两融数据显示，当日春立医疗获融资买入额403.64 万元，融资偿还707.33万元，融资净买入-303.69万元。截至11月19日，春立医疗融资融券余额合计 5179.45万元。 融资方面，春立医疗当日融资买入403.64万元。当前融资余额5179.45万元，占流通市值的0.70%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，春立医疗11月19日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 来源：新浪证券-红岸工作室 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组 ...

| | 股東類型 | 稅率 | 有關代預扣所得稅之更多補充 | | --- | --- | --- | --- | | | | | （如適用） | | 非居民企業 | | | | | （非中國內地登記地址） | | 10% | 本公司向H股的非居民企業股東派 | | | | | 發股息時須按10%稅率代扣代繳企 | | | | | 業所得稅。 | | 非個人居民 | | | | | （非中國內地登記地址） | | 10% | 本公司向H股的個人股東(香港或澳 | | | | | 門居民或其他與中國簽訂稅收協議 | | | | | 的國家的居民)派發股息時須按 | | | | | 10%稅率代扣代繳個人所得稅。 | | 內地個人投資者或內地證券投 | | 20% | 本公司向此類股東派發股息時須按 | | 資基金通過滬港通或深港通投 | | | 20%稅率代扣代繳個人所得稅。 | | 資本公司H股股票 | | | | | 發行人所發行上市權證/可轉換債券的相關信息 | | | | | 發行人所發行上市權證/可轉換債券 不適用 | | | | | 其他信息 | | | | | 其他信息 不適用 | | | | | ...